Published in Cardiovascular Week, April 19th, 2010
"Therefore, potent compounds to decrease CK2 activity to a non-pathogenic level would be a promising effort toward an...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.